Cantor Fitzgerald Analysts Cut Earnings Estimates for MNPR

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share estimate for Monopar Therapeutics to ($1.35), down from a previous forecast of ($1.30), while maintaining an Overweight rating and a price target of $74.00.
• Monopar Therapeutics reported a quarterly earnings per share of ($0.35), surpassing analyst expectations of ($0.47), as the stock was recorded trading down 2.9%.
• Insider trading activity included the sale of 42,504 shares worth approximately $1.7 million over the last quarter, reflecting a significant reduction in ownership stakes among key executives.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will earn ($1.35) per share for the year, down from their prior forecast of ($1.30). Cantor Fitzgerald currently has a "Overweight" rating and a $74.00 price target on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Monopar Therapeutics' FY2026 earnings at ($2.83) EPS.

A number of other brokerages also recently issued reports on MNPR. Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Monopar Therapeutics in a research note on Wednesday. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Monopar Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $60.00.

Monopar Therapeutics Stock Down 2.9%

MNPR traded down $1.03 on Friday, hitting $34.83. 1,377 shares of the company traded hands, compared to its average volume of 39,515. The company has a 50 day moving average of $38.04 and a 200-day moving average of $37.87. The stock has a market capitalization of $214.90 million, a PE ratio of -10.46 and a beta of 1.05. Monopar Therapeutics has a 12-month low of $2.15 and a 12-month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.12.

Insider Transactions at Monopar Therapeutics

In related news, Director Kim R. Tsuchimoto sold 8,904 shares of Monopar Therapeutics stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director owned 11,486 shares in the company, valued at approximately $459,440. This trade represents a 43.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Chandler Robinson sold 16,800 shares of Monopar Therapeutics stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the chief executive officer owned 73,472 shares in the company, valued at $2,938,880. The trade was a 18.61% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock worth $1,700,160 over the last quarter. 20.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics in the second quarter valued at $34,000. AlphaQuest LLC purchased a new position in Monopar Therapeutics in the first quarter valued at about $44,000. JPMorgan Chase & Co. purchased a new position in Monopar Therapeutics in the fourth quarter valued at about $45,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics in the second quarter valued at about $80,000. Finally, New York State Common Retirement Fund purchased a new position in Monopar Therapeutics in the second quarter valued at about $104,000. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.